Advertisement

Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81
Financing › Details

Cerevance–SEVERAL: investment, 202004 financing round Series B $45m with new investors GV + Bill Gates + Foresite Capital plus existing investors

 

Period Period 2020-04-14
  Predecessor Cerevance–SEVERAL: investment, 201612 financing round Series A $21.5m from Takeda + Lightstone Ventures
Organisations Money taker Cerevance LLC
  Group Cerevance (Group)
  Money source SEVERAL
Product Product  venture capital
Person Person Gates, William Henry (Bill), III
     

Cerevance. (4/14/20). "Press Release: Cerevance Closes $45 Million Series B Financing". Boston, MA.

Proceeds to Fund a Diverse Pipeline of Therapeutics Acting on Novel Targets for Brain Diseases


Cerevance, a private drug discovery and development company focused on brain diseases, has closed a Series B financing, bringing in $45 million from new investors including GV (formerly Google Ventures), Bill Gates and Foresite Capital, as well as all of the company’s previous investors, which include Takeda Ventures, Inc., the corporate venture arm of Takeda Pharmaceutical Company, Ltd., the Dementia Discovery Fund and Lightstone Ventures.

Cerevance will use the proceeds of the financing to continue identifying novel therapeutic targets for central nervous system diseases, such as Alzheimer’s disease, by transcriptionally and epigenetically profiling specific neuronal and glial cell populations in thousands of post-mortem human brain tissue samples and advancing a diverse portfolio of therapeutic programs against them.

“Cerevance has a differentiated approach to neurotherapeutics and continues to apply its powerful NETSseq platform to central nervous system diseases,” said David Schenkein, M.D., General Partner at GV. “With exceptional science, a strong sense of urgency and a leadership team that has previously succeeded together in drug discovery, Cerevance is well-positioned to deliver life-changing therapeutics for patients with brain diseases.”

“It’s hard to imagine a more stellar group of investors supporting us,” said Brad Margus, chief executive officer of Cerevance. “We look forward to drawing on their expertise in deep data analysis and therapeutic development as we mine our unique biological data sets to advance new, desperately needed therapies for brain diseases.”


About Cerevance

Cerevance, a private, clinical-stage pharmaceutical company focused on brain diseases, is applying a new technology, called NETSseq, to reveal transcriptional and epigenetic differences between specific cell types in mature human brains. NETSseq profiles neuronal and glial cell populations at depths not possible with other approaches, generating unprecedented data sets and insights. The company has thus far partnered with 14 brain banks around the world to assemble a growing collection of more than 7,000 clinically annotated, human brain tissue samples from healthy and diseased donors spanning nine decades in age. By applying NETSseq to specific cell types critical to circuits disrupted by disease and comparing vulnerable and resilient cell populations, Cerevance’s scientists have begun identifying targets and advancing a pipeline of novel therapeutics that modulate them for CNS diseases.

All trademarks used or mentioned in this release are protected by law.


Contacts

Cerevance:
Robert Middlebrook, +1-408-220-5722

Media:
Andrew Mielach, amielach@lifescicomms.com, +1- 646-876-5868

   
Record changed: 2020-04-18

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Cerevance (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top